130 related articles for article (PubMed ID: 22821211)
1. Oncogenic mutations in extramammary Paget's disease and their clinical relevance.
Kang Z; Xu F; Zhang QA; Wu Z; Zhang X; Xu J; Luo Y; Guan M
Int J Cancer; 2013 Feb; 132(4):824-31. PubMed ID: 22821211
[TBL] [Abstract][Full Text] [Related]
2. Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease.
Kang Z; Xu F; Zhang QA; Lin J; Wu Z; Zhang X; Luo Y; Xu J; Guan M
Mod Pathol; 2012 Aug; 25(8):1160-8. PubMed ID: 22522847
[TBL] [Abstract][Full Text] [Related]
3. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.
Gatalica Z; Vranic S; Krušlin B; Poorman K; Stafford P; Kacerovska D; Senarathne W; Florento E; Contreras E; Leary A; Choi A; In GK
Cancer Med; 2020 Feb; 9(4):1441-1450. PubMed ID: 31899853
[TBL] [Abstract][Full Text] [Related]
5. PI3K, Rac1 and pPAK1 are overexpressed in extramammary Paget's disease.
Qian Y; Zhang N; Chen S; Chu S; Feng A; Liu H
J Cutan Pathol; 2012 Nov; 39(11):1010-5. PubMed ID: 22845716
[TBL] [Abstract][Full Text] [Related]
6. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
8. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
9. Expression of insulin-like growth factor-1 receptor, p-AKT and p-ERK1/2 protein in extramammary Paget's disease.
Liu H; Moroi Y; Yasumoto S; Kokuba H; Imafuku S; Koga T; Masuda T; Tu Y; Furue M; Urabe K
Br J Dermatol; 2006 Sep; 155(3):586-91. PubMed ID: 16911286
[TBL] [Abstract][Full Text] [Related]
10. MUC5AC expression correlates with invasiveness and progression of extramammary Paget's disease.
Hata H; Abe R; Hoshina D; Saito N; Homma E; Aoyagi S; Shimizu H
J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):727-32. PubMed ID: 23581859
[TBL] [Abstract][Full Text] [Related]
11. erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget's disease.
Takata M; Fujimoto A; Aoki H; Hatta N; Ooi A; Takehara K
J Invest Dermatol; 1999 Aug; 113(2):258-62. PubMed ID: 10469313
[TBL] [Abstract][Full Text] [Related]
12. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
13. PIG7/LITAF gene mutation and overexpression of its gene product in extramammary Paget's disease.
Matsumura Y; Matsumura Y; Nishigori C; Horio T; Miyachi Y
Int J Cancer; 2004 Aug; 111(2):218-23. PubMed ID: 15197774
[TBL] [Abstract][Full Text] [Related]
14. Concordant overexpression of p-FAK and p-ERK1/2 in extramammary Paget's disease.
Chen SY; Moroi Y; Urabe K; Takeuchi S; Kido M; Hayashida S; Uchi H; Uenotsuchi T; Tu YT; Furue M
Arch Dermatol Res; 2008 Apr; 300(4):195-201. PubMed ID: 18210145
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
[TBL] [Abstract][Full Text] [Related]
16. Identification of genetic alterations in extramammary Paget disease using whole exome analysis.
Kiniwa Y; Yasuda J; Saito S; Saito R; Motoike IN; Danjoh I; Kinoshita K; Fuse N; Yamamoto M; Okuyama R
J Dermatol Sci; 2019 Apr; 94(1):229-235. PubMed ID: 31023612
[TBL] [Abstract][Full Text] [Related]
17.
Goto K; Maeda D; Kudo-Asabe Y; Hibiya T; Hayashi A; Fukayama M; Ohashi K; Goto A
J Clin Pathol; 2017 May; 70(5):424-427. PubMed ID: 27742746
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological study of invasive extramammary Paget's disease: subgroup comparison according to invasion depth.
Shiomi T; Noguchi T; Nakayama H; Yoshida Y; Yamamoto O; Hayashi N; Ohara K
J Eur Acad Dermatol Venereol; 2013 May; 27(5):589-92. PubMed ID: 22364152
[TBL] [Abstract][Full Text] [Related]
20. miR-31 is distinctively overexpressed in primary male extramammary Paget's disease.
Guo H; Qi RQ; Lv YN; Wang HX; Hong YX; Zheng S; Li JH; Gao XH; Chen HD
Oncotarget; 2016 Apr; 7(17):24559-63. PubMed ID: 27016415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
